Menu Search
Equities

MustGrow Biologics Corp

MGRO:CVE

MustGrow Biologics Corp

Actions
  • Price (CAD)1.81
  • Today's Change-0.03 / -1.63%
  • Shares traded11.93k
  • 1 Year change+63.06%
  • Beta1.3808
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in CAD

The one analyst offering a 12 month price target expects MustGrow Biologics Corp share price to rise to 5.60 in the next year from the last price of 1.84.
High204.3%5.60
Med204.3%5.60
Low204.3%5.60

Earnings history & estimates in CAD

On Aug 28, 2024, MustGrow Biologics Corp reported 2nd quarter 2024 losses of -0.02 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 2nd quarter results by 16.67%.
The next earnings announcement is expected on Nov 27, 2024.
Average growth rate-33.33%
MustGrow Biologics Corp reported annual 2023 losses of -0.01 per share on Apr 23, 2024.
Average growth rate+16.88%
More ▼

Revenue history & estimates in CAD

MustGrow Biologics Corp. did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate-33.33%
MustGrow Biologics Corp. had revenues for the full year 2023 of 4.71m. This was 78,433.33% above the prior year's results.
Average growth rate+78,433.33%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.